Drug Profile
SP 420
Alternative Names: SP-420Latest Information Update: 05 Jan 2024
Price :
$50
*
At a glance
- Originator University of Florida
- Developer Pharmacosmos; Sideris Pharmaceuticals
- Class Small molecules
- Mechanism of Action Iron chelating agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Iron overload
Most Recent Events
- 06 Dec 2023 The University of Texas Health Science Center at San Antonio and Abfero Pharmaceuticals suspends a phase I trial in Iron overload in the US due to hold on the study by FDA in US (PO) (NCT04741542) .
- 05 Sep 2023 Phase-II clinical trials in Iron overload in Italy, Greece, Denmark, Australia, Asia, Middle East, North America (PO) , NCT05693909, EudraCT2022-002395-36)
- 23 Jan 2023 Pharmacosmos A/S plans phase II trial in Beta-thalassemia (PO) in February 2023 (NCT05693909)